Could the NSW Truvada trial spell the beginning of the end for HIV?
Could a NSW trial of HIV prevention drug Truvada be the beginning of the end for HIV infection in Australia?
More than 1,100 men across NSW are participating in Australia’s largest clinical trial of the pre-exposure prophylaxis (PrEP) drug to protect themselves against HIV.
The daily pill protects the user from contracting the infection with an effectiveness rate of 99%, assisting the prevention of HIV transmission to partners.
So how soon could we see Truvada easily accessible to those at risk?
To find out more, we were joined by ACON director of HIV and Sexual Health Karen Price.
